

---

Subject                      **Programme and Policy Committee Chair Report**

---

Category                    **For Information**

---

### **Section A: Introduction**

- This report provides the Board with an overview of the activities of the Programme and Policy Committee (PPC) since the Committee Chair last reported to the Board in July 2025.
- The PPC held an in-person meeting on 29-30 October 2025. During the meeting, the Committee discussed a number of important topics for the Alliance and agreed on recommendations which are being put forward to the Board at its 3-4 December 2025 meeting for consideration.
- At the meeting on 29-30 October, under the Follow-up on Gavi 6.0 recalibration agenda item, the PPC endorsed the establishment of a Task Team to convene immediately after the PPC meeting, in order to develop recommendations for the Board in December 2025 on the Country Vaccine Budgets (CVBs) on the design and allocation approach, including to develop: a) the definition of guaranteed programmes, and b) the approach for discretionary allocation). The PPC approved the appointment of the PPC Chair as Chair of the Task Team and endorsed the composition of the CVB Task Team, which includes representatives from WHO, UNICEF, the Gates Foundation, the World Bank, the Implementing Countries Constituency, the Donors Constituency, Civil Society Organisations (CSOs), research and technical health institutes, and independent experts.
- Under the same agenda item, the PPC highlighted an urgent need to review and provide guidance to the Board, in advance of the December 2025 Board meeting, on the **market shaping savings committed for Gavi 6.0 under Strategic Goal 4** (“Ensure healthy markets for vaccines and related products”) including with respect to the US\$ 150 million requested by the Board at its Retreat in July 2025 and the US\$ 140 million of higher risk savings requested by the Board in April 2024). The PPC requested that the Board Chair consider the best governance pathway to provide this guidance, and the Board Chair, Professor Barroso, has requested that the Market Sensitive Decisions Committee (MSDC) members meet ***in an advisory capacity on a time limited basis***, to provide guidance on trade-offs and risks linked to expected savings under Strategic Goal 4.
- The PPC Chair report is attached in the form of a presentation as Annex A and the PPC recommendations to the Board are attached as Annex B.



## **Annexes**

**Annex A:** PPC Chair report

**Annex B:** PPC recommendations to Gavi Alliance Board

# PROGRAMME AND POLICY COMMITTEE CHAIR REPORT

BOARD MEETING

**Anne Schuchat**

3-4 December 2025, Geneva, Switzerland

# PPC Meeting, 29-30 October 2025

## Discussion, Guidance and Information Items

- CEO Update, including Strategy, Programmes and Partnerships
- Read out from the Audit and Finance Committee (short information item)
- Joint Alliance Update on Country Delivery
- Gavi 6.0 Operationalisation: Country Vaccine Budgets (including Portfolio Optimisation and Prioritisation), and Market Shaping Strategy
- Update on Measurement, Evaluation and Learning

# PPC Meeting, 29-30 October 2025

## Recommendation Items

- Follow-up on Gavi 6.0 Recalibration Retreat
- Gavi 6.0 Operationalisation: Fiduciary Risk Assurance and Financial Management Capacity Building
- Country Delivery: Nigeria, Papua New Guinea, and Venezuela
- Update on African Vaccine Manufacturing Accelerator
- Higher Valency Human Papillomavirus (HPV) Vaccines (HPV9+): Investment Case for Inclusion on the Gavi Product Menu

# Thank you

# REVIEW OF DECISIONS

PROGRAMME AND POLICY COMMITTEE  
29-30 October 2025, Geneva, Switzerland

# Decision 1: Follow up on Gavi 6.0 Recalibration Retreat (1/3)

Annex B

The Gavi Alliance Programme and Policy Committee **endorsed** the establishment of a Task Team to convene immediately in order to develop recommendations for the Board in December 2025 on the Country Vaccine Budgets (CVB) on design and allocation approach (including to develop: a) the definition of guaranteed programmes, and b) the approach for discretionary allocation). The PPC also endorsed the proposed chair and proposed composition of the CVB Task Team.

The Gavi Alliance Programme and Policy Committee **recommended** to the Gavi Alliance Board that it:

- a) **Approve** Strategy Goal 1 recalibration approach to scoping and pacing for malaria, hexavalent, measles/measles-rubella, cholera and inactivated polio vaccine programmes that was revised post-retreat based on technical consultations attached as Annex D to Doc 05, and the additional work to be undertaken through the CVB Task Team;
- b) **Approve** updates to Gavi's Fragility, Emergencies and Displaced Populations (FED) Policy following Fragile & Humanitarian (F&H) Approach approval attached as Annex C to Doc 05, as amended by the PPC;



# Decision 1: Follow up on Gavi 6.0 Recalibration Retreat (2/3)

Annex B

- c) **Approve** a minimum floor of US \$5 million and maximum cap of US \$120 million allocated to countries through the Health System and Immunisation Strengthening Support (HSIS) allocation formula as recommended in Annex B to Doc 05;
- d) **Approve** the ~US\$ 200 million reduction to the forecast of outbreak response stockpile;
- e) **Approve** the funding of ~US\$ 100 million co-financing waivers through the Fragile & Humanitarian (F&H) Approach; and **request** the F&H Alliance Advisory Group to prepare a proposal on prioritising the use cases of the F&H Approach for consideration by the PPC at its meeting in May 2026; and
- f) **Temporarily pause** during 2026 campaign co-financing requirements for campaigns for Initial Self-Financing countries, contingent on updated resource implications (current estimate is approximately US\$ 7-8 million).

# Decision 1: Follow up on Gavi 6.0 Recalibration Retreat (3/3)

Annex B

The Gavi Alliance Programme and Policy Committee also:

- g) Requested** the Secretariat and partners to develop a **broader strategic approach to improve campaign effectiveness** for consideration at the PPC meeting in May 2026, which:

  - Defines and incentivises sustainable alternatives to campaigns (including intra-campaign activities such as outreach intensification activities and Periodic Intensification of Routine Immunisation (PIRIs); and
  - Recalibrates the campaign cofinancing policy;
- h) Noted**, that in advance of the December 2025 Board meeting, there is an urgent need to review and provide guidance to the Board on the **market shaping savings committed for Gavi 6.0** (including with respect to the US\$ 150 million requested by the Board at its Retreat in July 2025 and the US\$ 140 million of higher risk savings requested by the Board in April 2024) and **requested** that the Board Chair consider the best governance pathway to provide this guidance; and
- i) Noted** the approach to manage the pipeline of applications from countries for vaccine introductions and preventative campaigns until Gavi transitions to its new funding model in Gavi 6.0. The unfreezing of additional applications from that pipeline beyond the urgent and special cases identified in the approach in Doc 05 will be considered following the Board approval of vaccine programmes to be guaranteed in CVBs and the allocation approach to the CVBs, and the availability of the Gavi 6.0 financial forecast (v23.1).

# Decision 2: Fiduciary Risk Assurance and Financial Management Capacity Building

Annex B

The Gavi Alliance Programme and Policy Committee **recommended** to the Gavi Alliance Board that it:

- a) **Approve** the approach as set forth in Annex E to Doc 06c to strengthen fiduciary risk assurance and financial management capacity building of Gavi grants during the Gavi 6.0 period; and
- b) **Approve** the associated investment of US\$ 110 million for 2026-2030.

# Decision 3: Country Delivery: Nigeria, Papua New Guinea, and Venezuela Annex B

The Gavi Alliance Programme and Policy Committee recommended to the Gavi Alliance Board that it:

- a) Approve that Nigeria sunsets its bespoke strategy on 31 December 2025 and returns to the preparatory transition phase from 01 January 2026, in full alignment with the ELTRACO policy;
- b) Approve that Papua New Guinea has a phased sunseting of its bespoke strategy whereby on 01 January 2026 it will be recognised as a Small Island Developing State (SIDS) which partly will apply for its vaccine portfolio, however, it will maintain its current cash allocation to the initial end date of the bespoke strategy 31 December 2027. This grandfathering arrangement is a blend of the bespoke strategy and the new classification (SIDS), hereby termed the hybrid ELTRACO policy application;
- c) Approve that the Gavi Secretariat leverages the WHO EPI review and the Gavi programmatic and financial audit instead of an external review of PNG's strategy; and
- d) Approve Venezuela as eligible to receive Gavi support under the Catalytic Phase.

# Decision 4: Update on African Vaccine Manufacturing Accelerator

The Gavi Alliance Programme and Policy Committee **recommended** to the Gavi Alliance Board that it **approve** the amendments to the key terms of AVMA as set out in Annex A to Doc 08 to add tuberculosis, mpox and respiratory syncytial virus (RSV) to the list of Priority Vaccines.

# Decision 5: Higher Valency Human Papillomavirus Vaccines (HPV9+): Investment Case for Inclusion on the Gavi Product Menu

The Gavi Alliance Programme and Policy Committee **recommended** to the Gavi Alliance Board that it:

**Approve** the inclusion of higher valency HPV vaccines (such as HPV9) on Gavi's product menu, subject to a second manufacturer's dossier being accepted for WHO Prequalification review (currently anticipated in 2026), in line with the market condition agreed by Alliance Partners, and Product Portfolio Management principles being met.





# Thank you